AU2006286476A1 - Novel azabicyclo(3.2.1)oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors - Google Patents

Novel azabicyclo(3.2.1)oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors Download PDF

Info

Publication number
AU2006286476A1
AU2006286476A1 AU2006286476A AU2006286476A AU2006286476A1 AU 2006286476 A1 AU2006286476 A1 AU 2006286476A1 AU 2006286476 A AU2006286476 A AU 2006286476A AU 2006286476 A AU2006286476 A AU 2006286476A AU 2006286476 A1 AU2006286476 A1 AU 2006286476A1
Authority
AU
Australia
Prior art keywords
oct
azabicyclo
ene
disorder
methylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006286476A
Other languages
English (en)
Inventor
Bjarne H. Dahl
Elsebet Ostergaard Nielsen
Dan Peters
John Paul Redrobe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of AU2006286476A1 publication Critical patent/AU2006286476A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2006286476A 2005-09-01 2006-08-30 Novel azabicyclo(3.2.1)oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors Abandoned AU2006286476A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200501218 2005-09-01
DKPA200501218 2005-09-01
US71336705P 2005-09-02 2005-09-02
US60/713,367 2005-09-02
PCT/EP2006/065804 WO2007025978A1 (en) 2005-09-01 2006-08-30 Novel azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Publications (1)

Publication Number Publication Date
AU2006286476A1 true AU2006286476A1 (en) 2007-03-08

Family

ID=38951394

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006286476A Abandoned AU2006286476A1 (en) 2005-09-01 2006-08-30 Novel azabicyclo(3.2.1)oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Country Status (13)

Country Link
US (1) US20100286193A1 (cg-RX-API-DMAC7.html)
EP (1) EP1937261B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009507002A (cg-RX-API-DMAC7.html)
CN (1) CN101267820A (cg-RX-API-DMAC7.html)
AR (1) AR057788A1 (cg-RX-API-DMAC7.html)
AT (1) ATE459354T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006286476A1 (cg-RX-API-DMAC7.html)
CA (1) CA2621162A1 (cg-RX-API-DMAC7.html)
DE (1) DE602006012711D1 (cg-RX-API-DMAC7.html)
DK (1) DK1937261T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ565469A (cg-RX-API-DMAC7.html)
TW (1) TW200744590A (cg-RX-API-DMAC7.html)
WO (1) WO2007025978A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE03446B1 (et) * 1995-10-13 2001-06-15 Neurosearch A/S 8-asabitsüklo[3.2.1]okt-2-eeni derivaadid, nende valmistamine ja kasutamine
GB9624611D0 (en) * 1996-11-26 1997-01-15 Zeneca Ltd Bicyclic amine compounds

Also Published As

Publication number Publication date
WO2007025978A1 (en) 2007-03-08
NZ565469A (en) 2010-11-26
CN101267820A (zh) 2008-09-17
US20100286193A1 (en) 2010-11-11
EP1937261A1 (en) 2008-07-02
JP2009507002A (ja) 2009-02-19
EP1937261B1 (en) 2010-03-03
CA2621162A1 (en) 2007-03-08
TW200744590A (en) 2007-12-16
DK1937261T3 (da) 2010-06-07
DE602006012711D1 (de) 2010-04-15
ATE459354T1 (de) 2010-03-15
AR057788A1 (es) 2007-12-19

Similar Documents

Publication Publication Date Title
EP2121678B1 (en) Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US8153797B2 (en) Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7687517B2 (en) 3,9-Diazabicyclo [3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US8049012B2 (en) 3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7638532B2 (en) 3-aryloxy-8-aza-bicyclo[3.2.1]oct-6-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1937261B1 (en) Novel azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US8110586B2 (en) 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2008025777A1 (en) Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1869033A1 (en) Novel enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors
EP1896468A1 (en) 3 -aryloxy- 8 -aza-bicyclo [3.2.1.] oct- 6- ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1896415A1 (en) Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2592130A1 (en) Novel naphthyl substituted azabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application